anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Severe ventriculomegaly is a rare congenital brain defect, usually detected in utero, of poor neurodevelopmental prognosis. This ventricular enlargement can be the consequence of different mechanisms: either by a disruption of the cerebrospinal fluid circulation or abnormalities of its production/absorption. The aqueduct stenosis is one of the most frequent causes of obstructive ventriculomegaly, however, fewer than 10 genes have been linked to this condition and molecular bases remain often unknown. We report here 4 fetuses from 2 unrelated families presenting with ventriculomegaly at prenatal ultra-sonography as well as an aqueduct stenosis and skeletal abnormalities as revealed by fetal autopsy. Genome sequencing identified biallelic pathogenic variations in LIG4, a DNA-repair gene responsible for the LIG4 syndrome which associates a wide range of clinical manifestations including developmental delay, microcephaly, short stature, radiation hypersensitivity and immunodeficiency. Thus, not only this report expands the phenotype spectrum of LIG4-related disorders, adding ventriculomegaly due to aqueduct stenosis, but we also provide the first neuropathological description of fetuses carrying LIG4 pathogenic biallelic variations.
The invention relates to a method for extracting the main active components of mulberry leaves and the application of extract, belonging to phytochemistry, Chinese medicine modernization and the field of preventing and treating diabetes mellitus. The invention is characterized in that only one resin is required and three kinds of the active components of the mulberry leaves, which are alkaloids, flavonoids and polysaccharide, are completely extracted by one extraction process. Therefore, the extracting method has simple technique and low cost. The preparation method comprises processes of extraction, adsorption, elution and drying. The main active components of the extract prepared by the method are the alkaloids, the flavonoids and the polysaccharide extracted from the mulberry leaves. The extract can be used as granule without excipient added or be used as the medicine or functional food with one or a plurality of edible excipient added, such as starch, microcrystalline cellulose, dextrin, sucrose, lactose, Vitamin C, citric acid and sodium sulfite, for preventing and treating diabetes mellitus and the complication of diabetes mellitus and obesity and treating viral col.
Clarithromycin is a semi-synthetic macrolide antimicrobial for oral use. Chemically, it is 6-0-methylerythromycin. The molecular formula is C38H69NO13, and the molecular weight is 747.96. The structural formula is:

Figure 1: Structure of Clarithromycin

Clarithromycin is a white to off-white crystalline powder. It is soluble in acetone, slightly soluble in methanol, ethanol, and acetonitrile, and practically insoluble in water.

Clarithromycin is available as, extended-release tablets.

Each yellow modified capsule shaped biconvex film coated clarithromycin extended-release tablet USP contains 500 mg of clarithromycin and the following inactive ingredients: colloidal silicon dioxide, D and C Yellow No. 10 aluminum lake, hydroxypropylcellulose, hypromellose, lactose monohydrate, magnesium stearate, povidone, propylene glycol, titanium dioxide. The imprinting ink contains iron oxide black, propylene glycol and shellac.

USP dissolution test is pending.
Group A will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting negative samples.
The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display \[HMD\] in delivering the VR intervention), audio, and motor equipment.
Small-cell lung cancer (SCLC) transformation accounts for 3-14% of resistance in EGFR-TKI relapsed lung adenocarcinomas (LUADs), with unknown molecular mechanisms and optimal treatment strategies. We performed transcriptomic analyses (including bulk and spatial transcriptomics) and multiplex immunofluorescence on pre-treated samples from LUADs without transformation after EGFR-TKI treatment (LUAD-NT), primary SCLCs (SCLC-P) and LUADs with transformation after EGFR-TKI treatment (before transformation: LUAD-BT; after transformation: SCLC-AT). Our study found that LUAD-BT exhibited potential transcriptomic characteristics for transformation compared with LUAD-NT. We identified several pathways that shifted during transformation, and the transformation might be promoted by epigenetic alterations (such as HDAC10, HDAC1, DNMT3A) within the tumor cells instead of within the tumor microenvironment. For druggable pathways, transformed-SCLC were proved to be less dependent on EGF signaling but more relied on FGF signaling, while VEGF-VEGFR pathway remained active, indicating potential treatments after transformation. We also found transformed-SCLC showed an immuno-exhausted status which was associated with the duration of EGFR-TKI before transformation. Besides, SCLC-AT exhibited distinct molecular subtypes from SCLC-P. Moreover, we constructed an ideal 4-marker model based on transcriptomic and IHC data to predict SCLC transformation, which obtained a sensitivity of 100% and 87.5%, a specificity of 95.7% and 100% in the training and test cohorts, respectively. We provided insights into the molecular mechanisms of SCLC transformation and the differences between SCLC-AT and SCLC-P, which might shed light on prevention strategies and subsequent therapeutic strategies for SCLC transformation in the future.
In group C, eligible subjects with advanced solid tumors whom are already on ICI with first unconfirmed PD on evaluation scans per investigator's assessment, will be randomised in a 1:1 ratio to receive MET-4 in addition to the PD-1/PD-L1 inhibitor as per SOC or control group. These subjects must be clinically stable and are to be continued on ICI at the discretion of the investigator. There will be no run-in period for this cohort. Subjects will be administered the same MET-4 dose as subjects in groups A and B.
This cohort consists of adult patients aged over 18 years who are admitted to the ICU at Epicura Hornu Hospital between October 14, 2024, and November 15, 2024 (to be updated). The study will investigate muscle thickness variations and fluid balance using ultrasound and bioelectrical impedance analysis (BIA). Informed consent will be obtained from the patients or their legal representatives.
PROBLEM TO BE SOLVED: To obtain a composition for a cosmetic, etc., excellent in proper hiding power, ultraviolet screening properties and dispersibility, providing a natural finish by using titanium dioxide having a specific average particle diameter and a specified surface area. SOLUTION: Titanium dioxide having >0.10μm and <=0.14μ average particle diameter and 10m<2> /g to 30m<2> /g specific surface area is prepared. The titanium dioxide comprises >=70wt.% based on the whole particles of titanium dioxide having a particle diameter of the average particle diameter ±0.03μm. When a composition is mixed with the titanium dioxide having a particle diameter in this range, excellent dispersion state is obtained. The composition mixed with the titanium dioxide, especially a cosmetic is further improved in feeling in use and optical properties such as ultraviolet light screening. The titanium dioxide may be subjected to surface treatment with a metal oxide, fluorine compound, a silicone-based finishing agent, wax, etc., depending upon purposes and used.  Two or more kinds of titanium dioxides different in particle diameter, specific surface area or shape may be combined and used.
INTRODUCTION: People with chronic pain are at increased risk of opioid misuse. Less is known about the unique risk conferred by each pain management treatment, as treatments are typically implemented together, confounding their independent effects. This study estimated the extent to which pain management treatments were associated with risk of opioid use disorder (OUD) for those with chronic pain, controlling for baseline demographic and clinical confounding variables and holding other pain management treatments at their observed levels.
METHODS: Data were analyzed in 2024 from 2 chronic pain subgroups within a cohort of non-pregnant Medicaid patients aged 35-64 years, 2016-2019, from 25 states: those with (1) chronic pain and physical disability (CPPD) (N=6,133) or (2) chronic pain without disability (CP) (N=67,438). Nine pain management treatments were considered: prescription opioid (1) dose and (2) duration; (3) number of opioid prescribers; opioid co-prescription with (4) benzo- diazepines, (5) muscle relaxants, and (6) gabapentinoids; (7) nonopioid pain prescription, (8) physical therapy, and (9) other pain treatment modality. The outcome was OUD risk.
RESULTS: Having opioids co-prescribed with gabapentin or benzodiazepine was statistically significantly associated with a 37-45% increased OUD risk for the CP subgroup. Opioid dose and duration also were significantly associated with increased OUD risk in this subgroup. Physical therapy was significantly associated with an 18% decreased risk of OUD in the CP subgroup.
CONCLUSIONS: Coprescription of opioids with either gabapentin or benzodiazepines may substantially increase OUD risk. More positively, physical therapy may be a relatively accessible and safe pain management strategy.
Patients receive psilocybin PO with optional booster dose on day 0. Patients attend an individual prep visit on day -1 and an individual integration visit on day 1. Patients also attend group preparation visits on days -14, -7 and -1 and group integration visits on days 1, 8, 22 and 36.
PURPOSE: A system for managing health is provided to measure an exercise method, an exercise amount, a fat amount and a muscle amount suitable for each member in a health club, thereby providing the measured values to each member. CONSTITUTION: A plurality of cabinets(100a~100n) comprises an RFID tag and a display unit. The RFID tag stores data of members. The display unit displays information. A server(200) comprises an RFID reader reading data from the RFID tag. The server transmits training information, personal information and a control signal. A plurality of sports machines(300a~300m) are driven according to the information and the control signal received from the server.
<P>PROBLEM TO BE SOLVED: To provide a method for preparation and use of flaviviruses and their vaccines.  <P>SOLUTION: There is provided flaviviruses including one or more hinge region mutations that reduce viscerotropism of the flaviviruses. In one example of a chimeric flavivirus, the chimera includes a capsid and non-structural proteins of a first flavivirus and a pre-membrane and envelope proteins of a second flavivirus or Dengue virus including envelope protein mutations that reduce viscerotropism of the chmeric flavivirus. In the case of the Dengue virus, the mutation may be, for example, 202 or 204-site lysine of Dengue envelope amino acid. The amino acid may be replaced by arginine.  <P>COPYRIGHT: (C)2011,JPO&INPIT
1. A method for preparing an effervescent granulate comprising a pharmacologically active ingredient, and citric acid and sodium bicarbonate as effervescent system, by means of wet granulation in a fluid-bed granulator, comprising the steps of: I. feeding a mixture comprising said active ingredient, citric acid and sodium bicarbonate into the said granulator which is simultaneously fed with a flow of air heated to about 70 degree C(+3 degree C) and having a moisture content of < 1.0 g/kg; II. wetting the said mixture with nebulized water; III. evaporating off the nebulizing water; characterized in that said mixture includes ferrous gluconate (2) as said pharmacologically active ingredient, and said step II is carried out when said mixture has reached a temperature of about 35 degree C(+3 degree C), and in said step III the temperature of said mixture is kept substantially constant at 35 degree C(+3 degree C), the method further comprising the following steps: IV. repeating steps II and III until a granulate with the desired features is obtained; and drying the said granulate with air heated to about 80 degree C(+3 degree C) until its moisture content is <=0.5% by weight, 2. A method according to claim 7, characterized in that, in step I, the magnitude of the air flow rate is between 3200 and 3800 m<3>/hour for each batch of about 265 kg of mixture to be granulated. 3. A method according to claim 1 or 2, characterized in that, in step II, the flow rate of nebulized water is preferably between 500 and 2000 ml/min. 4. A method according to any one of the preceding claims 1 to 3, characterized in that, in step II, the pressure of the flow of nebulized water is about 3 atmospheres. (3 x 1.013 bar). 5. A method according to any of claims 1 to 4, characterized in that tile total amount of water used in step II does not exceed 2% by weight of the mixture to be granulated. 6. A method according to any of claims 1 to 5, characterized in that the amount of nebulized water in each step does not exceed 0.5% by weight of the mass being processed. 7. An effervescent granulate obtained according to any of the preceding claims, comprising from 7 to 35% by weight of ferrous gluconate(2), from 25 to 45% by weight of citric acid and from 15 to 25% by weight of sodium bicarbonate. 8. An effervescent granulate according to claim 7, characterized in that it also comprises from 5 to 18% by weight of sorbitol, about 2% by weight of L-leucine and from 5 to 18% by weight of flavourings. 9. A granulate according to claim 7, characterized in that the ferrous gluconate is in the form of the dihydrate. 10. A tablet obtained by tabletting an effervescent granulate which is obtained according to any one of the preceding claims 1 to 6, the said tablet comprising from 7 to 35% by weight of ferrous gluconate, from 25 to 45% by weight of citric acid, from 15 to 25% by weight of sodium bicarbonate, from 5 to 18% by weight of sorbitol, about 2% by weight of L-leucine and from 5 to 11% by weight of flavourings.
The threat of premature labour is the main cause of hospitalization during pregnancy (38% of hospitalizations). To date, the assessment of severity relies mainly on ultrasound measurement of the cervix. The length of the cervix is significantly correlated with the risk of spontaneous premature delivery. A threshold of 25mm is relevant to rule out a delivery within 7 days but the identification of new markers including biological would be interesting to guide the clinician in assessing the risk of preterm birth. Among the biomarkers measured in vaginal secretions, the detection of fetal fibronectin seems to be the most relevant because of a high negative predictive value (NPV) up to 100% to rule out a delivery within 7 days. However, the use of this test is discussed because of its low positive predictive value (PPV) to predict delivery within 7 days (from 11% to 48%). The use of Premaquick © test (Biosynex, Strasbourg, France), which allow the simultaneous quantification of IL-6, total IGFBP-1 and native IGFBP-1 could be more efficient compared to the detection of fibronectin by improving the VPP. The results already obtained on a cohort of 97 patients (Eleje et al., 2016) show a similar NPV and a higher PPV of the Premaquick© test compared to the Quikcheck fFN ™ test (PPV up to 95% when the 3 markers are positive). Investigator wish to conduct a comparative study between these two tests on a larger cohort of patients (n = 220). Results of the tests will be masked for the clinician and the patient in order to assess and compare their ability to predict delivery within 7 days without modify the current medical management.
One microneedle device sample will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1 and at Weeks 2 and 4. Two skin biopsies of 4 mm will be performed on Day 1. No investigational drug product will be administered during this study.
The use of acellular nerve allografts (ANAs) to reconstruct long nerve gaps (>3 cm) is associated with limited axon regeneration. To understand why ANA length might limit regeneration, we focused on identifying differences in the regenerative and vascular microenvironment that develop within ANAs based on their length. A rat sciatic nerve gap model was repaired with either short (2 cm) or long (4 cm) ANAs, and histomorphometry was used to measure myelinated axon regeneration and blood vessel morphology at various timepoints (2-, 4- and 8-weeks). Both groups demonstrated robust axonal regeneration within the proximal graft region, which continued across the mid-distal graft of short ANAs as time progressed. By 8 weeks, long ANAs had limited regeneration across the ANA and into the distal nerve (98 vs. 7583 axons in short ANAs). Interestingly, blood vessels within the mid-distal graft of long ANAs underwent morphological changes characteristic of an inflammatory pathology by 8 weeks post surgery. Gene expression analysis revealed an increased expression of pro-inflammatory cytokines within the mid-distal graft region of long vs. short ANAs, which coincided with pathological changes in blood vessels. Our data show evidence of limited axonal regeneration and the development of a pro-inflammatory environment within long ANAs.
The invention discloses a Chinese traditional medicinal injection for curing cancers and a preparation method thereof. The Chinese traditional medicinal injection is prepared from 0.9 to 2.1 parts of cantharis, 30 to 70 parts of ginseng, 60 to 140 parts of milk veteh and 90 to 210 parts of acanthopanax. Ginseng, milk veteh and acanthopanax are aqueously extracted and ethanol extracted respectively. The extracted solution is condensed, and micro-filtered with an inorganic ceramic membrane before the extracted solution is refined with polyamide resin; then the refined solution is hyperfiltrated with an organic membrane, and is mixed with aqueous extract of cantharis. In this way, the Chinese traditional medicine injection is prepared. By comparing the invention with the prior art, in the method for preparing the Chinese traditional medicine injection, the medicinal materials are aqueously extracted and ethanol extracted; the extracted solution is purified, separated and condensed by combining the membrane separation technology and refining with resin; accordingly, the Chinese traditional medicine injection is rich in effective ingredients. By substituting the physical method for the traditional chemical process, macromolecular substance in the extracted solution of the Chinese traditional medicine can be effectively removed without introducing other inorganic ions, thus keeping the characteristics of the compound preparation of the Chinese traditional medicine, and effectively reducing the adverse effect of the medicaments, improving the curative effect, and improving and ensuring the product quality.
An antihelminthic agent contains, as active ingredient, an aryloxy acetyl benzimidazole deriv. of formula (I), or its (where R1 is alkyl, allyl or propargyl; R2 is u-3C alkylene or -NH-CO-R4; R4 is 1-3C alkylene; Z and R3 are H, halogen, alkyl, alkoxy or nitro; m is 1-4, n is 1-5, X is either not present in an (in)organic acid). The agent canbbe used to treat helminthic disease cattle, sheep, goats, pigs, horses, poultry, dogs, hunting and laboratory animals. (I) are of low toxicity LD50 = 4.8-9.9 g/kg body wt. Suitable doses are 0.05-0.5 g/kg p.o. The cpds. have a low comutation coefficient and the animals do not become accustomed to them. (I) are not allergic or teratogenic and in therapeutic doeses have no effect on the antitoxic function of the liver. (I) also inhibit the toxic effect of CNS stimulators of caffein corasol and strychnine and prolong the effect of depressives, of chloral hydrate and hexenal.
FIELD: medicine. SUBSTANCE: desired products have common formulawhere n= 0,2,3; R is allyl, dialkylamino- or nitrogen-containing heterocycles, Rand Rare the same or different and represent H, lower alkyls and alkoxy. Desired derivatives are prepared by alkylation of 2-mercaptobenzimidazoles with appropriate alkylating agent. The process is followed by treatment thus prepared bases with hydrogen chloride. Said derivatives or their pharmaceutically acceptable salts has anxyolytic action and are low toxic. EFFECT: creates novel derivatives of 2-mercaptobenzimidazole having selective anxyolytic activity.
Initiation of QBRELIS in patients on diuretics may result in excessive reduction of blood pressure. The possibility of hypotensive effects with QBRELIS can be minimized by either decreasing or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with QBRELIS. If this is not possible, reduce the starting dose of QBRELIS [see Dosage and Administration ( 2.2) and Warnings and Precautions ( 5.4)] . 

QBRELIS attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, monitor the patient’s serum potassium frequently.
The hippocampus plays an essential role in long-term episodic memory by supporting the recollection of contextual details, whereas surrounding regions such as the perirhinal cortex support familiarity-based recognition discriminations. Working memory - the ability to maintain information over very brief periods of time - is traditionally thought to rely heavily on frontoparietal attention networks, but recent work has shown that it can also rely on the hippocampus. However, the conditions in which the hippocampus becomes involved in working memory tasks are unclear and whether it contributes to recollection or familiarity-based responses in working memory is only beginning to be explored. In the current paper, we first review and contrast the existing amnesia literature examining recollection and familiarity in episodic and working memory. The results indicate that recollection and familiarity contribute to both episodic and working memory. However, in contrast to episodic memory, in working memory the hippocampus is particularly critical for familiarity-based rather than recollection-based discrimination. Moreover, the results indicate that the role of the hippocampus in working memory can be obscured due to 'criterion-induced process-masking' because it primarily supports intermediate-confidence recognition decisions. We then report results from a new working memory study examining the ability of amnesics to detect global and local changes in novel complex objects (i.e., fribbles), which indicates that the hippocampus plays an especially critical role in working memory when the task requires the detection of global rather than discrete changes. We conclude by considering the results in light of neurocomputational models and proposing a general framework for understanding the relationship between episodic and working memory.